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Background: Invariant natural killer T (iNKT) cells are CD1d-restricted T cells, which respond rapidly to antigen
recognition and promote development of anti-tumor immunity in many tumor models. Surprisingly, we previously
found that mice deficient in iNKT cells developed spontaneous CD8+ T cells responses partially effective at inhibiting
metastases in mice bearing the 4T1 mammary carcinoma, and showed a markedly improved response to treatment
with local radiotherapy and anti-CTLA-4 antibody compared to wild type (WT) mice.
Methods: To understand the mechanisms of the immunosuppressive function of iNKT cells, dendritic cells (DCs)
were analyzed by immunohistochemistry and flow cytometry in WT and iNKT-deficient (iNKT−/−) mice. The effects
of antibody-mediated blockade of CD1d on DC number and phenotype, priming of anti-tumor T cells, and tumor
response to treatment with local radiotherapy and anti-CTLA-4 antibody were evaluated. To determine if the improved
response to treatment in the absence of iNKT cells was independent from the immunotherapy employed, 4T1-tumor
bearing WT and iNKT−/− mice were treated with local radiotherapy in combination with antibody-mediated CD137
co-stimulation.
Results: DCs in 4T1 tumors and tumor-draining lymph nodes but not distant lymph nodes were significantly
reduced in WT mice compared to iNKT−/− mice (p < 0.05), suggesting the selective elimination of DCs cross-presenting
tumor-associated antigens by iNKT cells. Consistently, priming of T cells to a tumor-specific CD8 T cell epitope in mice
treated with radiotherapy and anti-CTLA-4 or anti-CD137 was markedly enhanced in iNKT−/− compared to WT mice.
CD1d blockade restored the number of DC in WT mice, improved T cell priming in draining lymph nodes and
significantly enhanced response to treatment.
Conclusions: Here we describe a novel mechanism of tumor immune escape mediated by iNKT cells that
limit priming of anti-tumor T cells by controlling DC in tumors and draining lymph nodes. These results have
important implications for the design of immunotherapies targeting iNKT cells.
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Natural killer T (NKT) cells comprise a subset of lympho-
cytes originating from a distinct developmental lineage [1]
which bridge innate and adaptive immunity and modulate
immune responses in autoimmunity, malignancies and in-
fections [2]. Although initially identified by co-expression
of conventional αβ T-cell receptors (TCR) and markers
typically associated with natural killer (NK) cells [3], NKT
are currently distinguished on the basis of CD1d restric-
tion as well as specific usage of TCRα chains [4]. In both
mice and humans, most NKT cells express TCRs formed
by the rearrangement of a canonical α chain (Vα14 in
mice, Vα24 in humans) and a limited set of Vβ chains
(Vβ.2, Vβ7, Vβ2 in mice, Vβ11 in humans) and are com-
monly referred to as type I or invariant natural killer T
(iNKT) cells [5,6]. A smaller NKT cell subset utilizes a
more diverse set of TCR αβ chains and is referred to as
type II or non-invariant NKT cells [7].
Identification of α-galactosylceramide (α-GalCer) as a
strong agonist selective for iNKT cells [8] facilitated their
characterization using α-GalCer-loaded CD1d tetramers
[9]. In several tumor models, iNKT cells were found to
perform important immunosurveillance functions and
become key effectors of tumor rejection when activated
by α-GalCer [10-13]. Expression of high levels of Fas
Ligand, perforin, and granzyme B by iNKT cells underlies
their cytolytic activity against CD1d+ tumor cells [14] and
myeloid cells with immunosuppressive function present in
the tumor microenvironment [15]. In addition, iNKT cells
exert anti-tumor functions by rapid and robust secretion
of cytokines that improve DC ability to cross-prime anti-
tumor T cells [10,12,16,17] and enhance recruitment of
other effectors such as NK cells, CD4+ T helper-1 (Th1)
and CD8+ cytotoxic T (CTL) cells [13,18].
Experimental data in different systems indicate a func-
tional plasticity of iNKT cells. iNKT cells can promote
the polarization of adaptive immune responses towards
both Th1 and Th2 and can secrete immunosuppressive
cytokines [19]. The regulatory function of iNKT cells has
been demonstrated in multiple models of autoimmune
diseases in which iNKT cells played essential roles in
maintenance of tolerance [20-22]. The mechanisms that
determine whether iNKT cells act to promote immune
activation or tolerance remain incompletely understood,
but the inflammatory context in which interactions of
iNKT cells with CD1d+ myeloid cells take place is thought
to be a key factor [23,24].
The 4T1 mouse mammary carcinoma is a model for
triple negative breast cancer and shows an aggressive
behavior with rapid spread of metastatic cells to the lungs
after subcutaneous injection. We previously found that
4T1 tumor-bearing iNKT-deficient (iNKT−/−) mice devel-
oped a spontaneous CD8+ T cell response that was par-
tially effective at controlling metastases in the lungs [25].Response to treatment with local radiotherapy and anti-
CTLA-4 monoclonal antibody (mAb) was also markedly
improved in iNKT−/− compared to wild type (WT) mice
with half of the mice rejecting completely the primary
irradiated tumor and lung metastases and showing long-
term survival compared to none of the WT mice [25].
These data implicated iNKT cells as major regulators of
the spontaneous as well as immunotherapy-elicited anti-
tumor immune response to 4T1 tumor.
CD4+ regulatory T cells (Treg) have been shown to limit
the development of anti-tumor T cells by killing DCs in
tumor-draining lymph nodes (dLN) [26]. DCs are a major
subset of CD1d+ antigen-presenting cells (APC) that inter-
act with iNKT cells. Therefore, we hypothesized that
iNKT cells may be limiting the anti-tumor immune re-
sponse in 4T1 tumor-bearing mice by controlling the
loco-regional population of DCs in the tumor and dLNs.
For the first time, we present evidence that WT mice have
reduced numbers of DCs in tumor and dLN compared to
iNKT−/− mice, and reduced priming of tumor-specific
CD8+ T cells, as measured by gamma interferon (IFNγ)
production in response to a H2-Ld-restricted peptide
derived from a tumor antigen. DC numbers and tumor-
specific CD8+ T cell responses were at least partially re-
stored by blocking CD1d, resulting in improved response
to immunotherapy. Overall, data demonstrate a novel
mechanism of immune escape mediated by iNKT cells.
Results
Numbers of DCs infiltrating 4T1 tumors and dLN are
lower in WT compared to iNKT−/− mice
We hypothesized that the interaction of iNKT cells with
CD1d+ APC could modulate the ability of WT mice to
develop anti-tumor immune responses upon treatment.
To test this hypothesis we compared DCs in healthy and
tumor-bearing WT and iNKT−/− mice. iNKT−/− mice
were generated by targeted deletion of the Jα18 segment
of the T-cell receptor (TCR) and show selective loss of
the Vα14Jα18 TCR expressed by iNKT cells while other
lymphoid and myeloid populations are not affected [27].
Consistently, there were no differences in the number of
DCs present in LNs or their expression of maturation
markers CD80 and CD86, including CD1d, between WT
and iNKT−/− healthy mice (Figure 1A and B). In con-
trast, after 4T1 tumor implantation there was a differ-
ence in the numbers of DCs in the tumor-draining but
not distant LNs (Figure 1C and D), with significantly
lower numbers of DCs present in WT compared to
iNKT−/− mice. Significantly lower numbers of DCs were
also found in the tumors growing in WT compared to
iNKT−/− mice (Figure 1E and F). Interestingly, while
non-draining LNs of iNKT−/− mice showed a DC density
comparable to LNs of healthy mice, DC density was









































































































Figure 1 iNKT cells regulate the number of DCs in 4T1 tumors and draining lymph nodes. (A, B) Lymph nodes collected from healthy WT
(black bars) and iNKT−/− (white bars) mice (N = 3/strain). (A) Full-face lymph node sections were stained with anti-CD11c mAb and positive cells
counted. (B) Dissociated lymph node cells were gated on CD11c + cells and expression of CD1d and co-stimulatory molecules CD80 and CD86
determined by flow cytometry. (C-F) WT (black bars) and iNKT−/− (white bars) mice were inoculated s.c. with 4T1 cells. On indicated days,
tumor-draining lymph nodes (C), non-draining lymph nodes (D), and tumors (E, F) were excised, tissue sections stained with anti-CD11c
mAb and positive cells counted. Numbers are the mean ± SD of 3 mice of each strain analyzed at each time point. (F) Representative
fields (400× magnification). Results are representative of two experiments. *p < 0.05.
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the growing tumor leads to some activation of the re-
gional immune system. This finding is consistent with
the presence of a spontaneous anti-tumor CD8+ T cell
response in iNKT−/− mice that was partially effective at
controlling metastases in the lungs as we have previously
reported [25].
Overall, data suggest that in WT mice iNKT cells may
control the population of DCs in the tumor and dLN
thus precluding the priming of anti-tumor T cells.
CD1d blockade restores DC numbers and improves
tumor-specific T cell cross-priming in WT 4T1
tumor-bearing mice
Elimination of DCs in dLN has been shown to be one
mechanism whereby Treg suppress the anti-tumor im-
mune response [26]. To determine if iNKT cells could
be responsible for the reduction in the number of DCs
in tumors and dLN of WT mice we tested whether inhi-
biting their interaction with DCs with a mAb that blocks
CD1d [28] would lead to increased DC numbers. First,
we confirmed that the anti-CD1d mAb used (20H2) was
able to inhibit the interaction of the DN32.D3 iNKT-like
hybridoma cells with α-GalCer-loaded DCs in vitro in a
dose-dependent manner (Additional file 1: Figure S1). Inaddition, we verified that administration of 20H2 mAb
to mice did not cause the depletion of CD1d+ cells
(Additional file 2: Figure S2) nor induce their stimula-
tion by reverse signaling (Additional file 3: Figure S3).
Next, anti-CD1d mAb was given to 4T1 tumor-bearing
WT mice starting on day 3 post-tumor inoculation and
tumors and dLN analyzed at day 13, a time when tumors
are irradiated in treated mice and the availability of DCs
that can cross-present the tumor antigens released by
radiation is critical [29,30]. CD1d blockade led to a sig-
nificant increase in the total number of DCs present in tu-
mors and dLNs (Figure 2A). Both immunostimulatory
CD8α + and CD8α- DC subsets were increased (Figure 2B),
whereas expression of activation markers CD40, CD70,
CD86, and of MHC Class I molecules in either subsets of
tumor infiltrating DCs were not altered by CD1d blockade
(Figure 2C-F). Therefore, data indicate that iNKT cells
regulate DC numbers in 4T1 tumor-bearing WT mice via
CD1d-mediated interactions.
To determine if blockade of CD1d resulted in im-
proved priming of anti-tumor CD8+ T cells in dLN of
WT mice treated with local radiotherapy and anti-
CTLA-4 mAb [25], we measured tumor antigen-specific
production of IFNγ by dLN cells stimulated with a CD8











































































































Figure 2 Blocking CD1d enhances DC numbers in 4T1 tumor-bearing WT mice. WT mice were inoculated with 4T1 cells on day 0. On days
3, 7 and 11 mice were given either PBS (A) or Isotype mAb (B-F) (black bars) or anti-CD1d mAb (A-F) (white bars) i.p. (A) Tumors and dLN were
excised on day 13, and tissue sections stained with anti-CD11c mAb. Numbers are the mean ± SD of 3 mice/group. Results are representative
of two experiments. (B-F) In a separate experiment using the same blocking regimen, tumors were digested for flow cytometry analysis
of dissociated cells (N = 9/group). To obtain sufficient material, each sample was prepared by pooling tumors from 3 mice, and 3 independent
samples/group analyzed. (B) Samples were gated on CD45 + CD11c + cells, and analyzed for expression of (B) CD8α, and (C) CD40, (D) CD86,
(E) CD70 and (F) MHC Class I molecules. *p < 0.05, **p < 0.005.
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mice that were untreated or treated with RT or anti-
CTLA-4 alone (Figure 3). However, the combination of
RT and anti-CTLA-4 induced significant tumor-specific
IFNγ production (p < 0.005 versus all other groups), as
expected given the therapeutic synergy we have previ-
ously shown with this combination [25,29,32]. Import-
antly, the response was significantly enhanced by
blockade of CD1d (mean IFN-γ 248.50 ± 67.41 pg/mL in
RT + anti-CTLA-4 + anti-CD1d versus 88.62 ± 19.80 pg/
mL in RT + anti-CTLA-4, p < 0.005). Interestingly, tumor
antigen-specific IFN-γ production was detected in dLNs
from untreated iNKT−/− mice (33.08 ± 10.04 pg/mL for
AH1-A5 versus 9.65 ± 10.86 pg/mL for pMCMV, p = 0.05)
(Figure 3), a finding consistent with the ability of these
mice to inhibit lung metastases in a CD8-dependent man-
ner [25]. This response was not affected by radiotherapy
or anti-CTLA-4 as single treatment, but was dramatically
increased by their combination (696.12 ± 109.22 pg/mL,
p < 0.001 versus control). Remarkably, IFNγ response
of dLN cells from mice treated with radiotherapy +
anti-CTLA-4 was seven fold higher in iNKT−/− com-
pared to WT mice.Overall, data strongly support the conclusion that
iNKT cells perform a regulatory function and hinder the
development of anti-tumor T cells in 4T1 tumor-bearing
mice by controlling DC population that cross-present
tumor-derived antigens in dLNs.
CD1d blockade improves response to treatment with
radiotherapy and anti-CTLA-4 in WT mice
Next, we investigated whether the improved anti-tumor
T cell response seen in the presence of CD1d blocking
mAb results in improved tumor response to treatment.
To this end, WT 4T1 tumor-bearing mice were treated
with RT + anti-CTLA-4 in the presence or absence of
CD1d blockade (Figure 4A). Treatment with RT and anti-
CTLA-4 was effective at controlling the primary irradiated
tumor and extending significantly mice survival compared
to control (median survival 41 versus 32.5 days, p < 0.05)
(Figure 4B and C), as previously shown [29]. However, no
complete tumor regression was achieved and all mice
eventually succumbed to metastases. CD1d blockade did
not have any effect by itself on tumor growth or survival,
but it improved control of the irradiated tumor (p < 0.05)
and survival (p < 0.05) of mice treated with RT and anti-












































Figure 3 CD1d blockade enhances IFN-γ response by
tumor-specific cells generated by RT + anti-CTLA-4 blockade.
WT or iNKT−/− mice were treated with local tumor radiotherapy in two
fractions of 12 Gy given on days 13 and 14 post-tumor inoculation.
Mice received anti-CTLA-4 mAb on days 15, 18 and 21. Some mice
additionally received anti-CD1d mAb on days 3, 7 and 11 post tumor
inoculation. Cells from tumor-draining lymph nodes were collected on
day 23 and stimulated with feeder cells pre-loaded with irrelevant
peptide pMCMV (open circles) or AH-1-A5 (filled circles). Secreted IFN-γ
in the supernatant was measured 48 hours later. Each symbol
represents an individual mouse. Bars indicate the mean ± SD of
5 mice/group. *p < 0.05, **p < 0.005, ***p < 0.0005.
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was seen in 25% of the mice and these mice survived
long-term and rejected a challenge of 4T1 cells 150 days
after the initial inoculum (data not shown). Interestingly,
CD1d blockade did not change significantly intra-tumoral
levels of TNF-α, IL-10, and IL-4 in mice treated with radi-
ation and anti-CTLA-4 (Figure 5B-D). IL-17 was un-
detectable in all conditions (data not shown). However,
CD1d blockade enhanced significantly the levels of IFNγ
induced in tumors by treatment with radiation and anti-
CTLA-4 (Figure 5A), suggesting that iNKT cells hinder
therapeutically effective Th1 responses in WT mice. Con-
sistently, intra-tumoral levels of IFNγ were high in iNKT−/−
mice treated with radiation and anti-CTLA-4 and were
not further increased by CD1d blockade. Similarly, IFNγ
was produced at significantly higher levels by spleen cells
from mice treated with radiation and anti-CTLA-4 upon
ex vivo activation in both WT and iNKT−/− mice, and it
was further increased by CD1d blockade in WT but not
iNKT−/− mice (Figure 6A). Interestingly, while IL-10 levels
were low and were not affected by any of the treatments,
IL-4 was produced at significantly higher levels by spleen
cells of mice treated with RT + anti-CTLA-4 compared to
control (Figure 6B and C). However, this effect was inde-
pendent from iNKT cells since IL-4 levels were similar inWT and iNKT−/− mice and were not enhanced by CD1d
blockade in WT mice.
Taken together, these results indicate that iNKT cells
can actively suppress the development and/or function of
anti-tumor T cells and impair response to anti-CTLA-4
immunotherapy in 4T1 tumor-bearing mice.
iNKT cells regulate the response of 4T1 tumor-bearing
mice to the combination of local radiotherapy and CD137
costimulation
To determine whether negative regulation by iNKT cells
could influence the response to a different immunother-
apy, we tested treatment with local radiotherapy in com-
bination with an agonistic anti-CD137 (4-1BB) mAb
(Figure 7A). CD137 is a member of the tumor necrosis
receptor superfamily that is upregulated shortly after
T-cell activation [33]. CD137 ligation delivers a strong
survival signal to T-cells, stimulates their effector func-
tion and promotes their differentiation into memory
cells [34-37]. Importantly, we previously demonstrated
that the combination of radiotherapy and CD137 costi-
mulation was significantly more effective than each treat-
ment alone in improving survival of mice with the
intracranial GL261 glioma achieving tumor eradication in
the majority of mice [38].
In both WT and iNKT−/− mice anti-CD137 mAb given
as a single agent did not enhance survival compared to
control untreated mice (median survival in WT mice:
39 days in control vs 40 days in anti-CD137 group, p =
0.36; iNKT−/− mice: 42 days in control vs 46 days in
anti-CD137 group, p = 0.33, Additional file 4: Figure S4).
Consistent with previous observations that radiotherapy
alone does not inhibit 4T1 lung metastases [29], median
survival in WT or iNKT−/− mice given radiotherapy was
not enhanced significantly (WT mice: 42 days, p = 0.75
compared to control; iNKT−/− mice: 40 days, p = 0.98
compared to control). In contrast, radiotherapy and anti-
CD137 in combination significantly prolonged survival in
WT (median survival 56 days, p < 0.05 compared to con-
trol) and iNKT−/− (median survival 60 days, p < 0.005
compared to control) mice (Figure 7C). Importantly, no
complete tumor regression was achieved in WT mice
treated with this combination and all mice eventually suc-
cumbed to metastases. In contrast, complete tumor re-
gression and long-term survival was achieved in 50% of
iNKT−/− mice treated with radiotherapy + anti-CD137
(Figure 7C). Furthermore, all of the long-term regressors
were able to reject a tumorigenic challenge of viable 4T1
cells 120 days after the initial tumor implantation, indicat-
ing that they had developed a long-lasting protective im-
munological memory to the tumor (Figure 7D). To
determine if blockade of CD1d in the context of radio-
therapy and CD137 costimulation resulted in improved
priming of anti-tumor CD8+ T cells in dLN of WT mice
B C
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Figure 4 CD1d blockade improves response of WT mice to treatment with radiotherapy and anti-CTLA-4. (A) WT 4T1 tumor-bearing mice
(N = 8 mice/group) were treated with local tumor radiotherapy in two fractions of 12 Gy given on days 13 and 14 post-tumor inoculation. Mice
received anti-CTLA-4 mAb on days 15, 18 and 21. Some mice additionally received anti-CD1d mAb on days 3, 7 and 11 post tumor inoculation.
(B) Tumor growth is shown for each group until the last day when all mice were alive, day 28 for control and anti-CD1d treated groups, and day
35 for RT + anti-CTLA-4-treated groups. Fractions indicate the number of mice showing complete tumor regression over the total in each group.
(C) Surviving tumor-free mice were followed until day 150. Data shown are from one of 2 independent experiments performed with similar
results. *p < 0.05, **p < 0.005.
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(Figure 3), we measured tumor antigen-specific produc-
tion of IFNγ by dLN cells. While mice treated with anti-
CD137 monotherapy did not show any peptide-specific
IFNγ production, treatment with the combination of RT
and anti-CD137 induced significant tumor-specific IFNγ
production in both WT and iNKT−/− mice (Figure 8). Im-
portantly, the response was markedly higher in iNKT−/−
mice and was significantly enhanced by in vivo blockade
of CD1d in WT (mean IFN-γ 109.03 ± 13.85 pg/mL in
RT + anti-CD137 + anti-CD1d versus 71.58 ± 17.06 pg/mL
in RT + anti-CD137, p < 0.05) but not iNKT−/− mice.
Overall, these results indicate that iNKT cells hinder
priming of tumor-specific CD8+ T cells independent of
the immune response modifier used in combination with
radiotherapy to treat 4T1 tumor-bearing mice.
Discussion
The 4T1 mouse mammary carcinoma is considered a
model for the aggressive triple negative subtype of hu-
man breast cancer [39]. 4T1 cells are highly metastatic
and relatively resistant to many immunotherapies once
established, including anti-CTLA-4 treatment [29]. Wehave previously shown that the combination of local
radiotherapy with anti-CTLA-4 induces a CD8+ T cell-
mediated anti-tumor response effective at controlling
the irradiated tumor as well as systemic metastases lead-
ing to increased survival of 4T1 tumor-bearing mice
[29,32,40]. However, cures were rarely seen and most
mice eventually succumbed to the tumor. Intriguingly,
response to radiotherapy and anti-CTLA-4 was mark-
edly improved in mice lacking iNKT cells, achieving
cures in 50% of the mice [25]. The improved response
could not be attributed to altered immunogenicity of
4T1 cells in iNKT−/− mice and could not be recapitu-
lated in WT mice by administration of α-GalCer, a po-
tent activator of iNKT cells anti-tumor activity in many
tumor models [12,13,41-44]. Here we show that the im-
proved response of 4T1 tumor-bearing mice seen in the
absence of iNKT cells is not unique to anti-CTLA-4-
based immunotherapy. Co-stimulation of T cells by anti-
CD137 in combination with radiotherapy was similarly
more effective in iNKT−/− than WT mice and resulted in
protective anti-tumor recall responses. These data fur-
ther establish a negative regulatory role of iNKT cells in

















































































Figure 5 CD1d blockade enhances intratumoral IFN-γ response induced by RT + anti-CTLA-4 blockade. WT and iNKT−/− mice were
treated with local tumor radiotherapy in two fractions of 12 Gy given on days 13 and 14 post-tumor inoculation. Mice received anti-CTLA-4 mAb
on days 15, 18 and 21. Some mice additionally received anti-CD1d mAb or isotype mAb on days 3, 7 and 11 post tumor inoculation. Tumors
were harvested at day 22 and concentration of (A) IFN-γ, (B) TNF-α, (C) IL-10 and (D) IL-4 were determined. Bars indicate the mean ± SD
of 4 mice/group. *p < 0.05.
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by iNKT cells we examined DC, which are largely CD1d+,
and are the APCs required for cross-presentation of
tumor antigens to T cells [45,46]. Surprisingly, there was a
reduction in the number of DCs present in the tumor and
dLN of WT mice compared to iNKT−/− mice (Figure 1).
Downregulation of surface CD11c molecules has been re-
ported in TLR-activated mouse DCs [47]. We did not see
any difference by flow cytometry in the levels of CD11c in
DCs isolated from non-draining LN, dLN and tumors
(not shown), suggesting that CD11c downregulation in-
duced by activation of DCs in the tumor of WT mice is
not likely to account for locoregional reduction of DCs.
Moreover, blocking the interaction of iNKT cells with DCs
with anti-CD1d mAb led to an increase in both CD8α +
(immunostimulatory) and CD8α- DCs in WT mice with-
out affecting their activation state as measured by expres-
sion of costimulatory molecules (Figure 2). Overall, data
indicate that iNKT cells regulate DCs numbers in the
tumor and dLN.
Clearance of APC has been proposed as a mechanism
to prevent unrestrained T-cell activation and prolifera-
tion, which is beneficial in preventing systemic auto-
immunity [48] but detrimental for anti-tumor responses
[49]. Several immune cells, including Tregs [26], NK
cells [50] and CD8+ CTLs [49,51], have been implicated
in direct elimination of DCs. We were unable to isolate
tumor-infiltrating iNKT in sufficient quantities to testtheir ability to kill DCs ex vivo, but human iNKT cells
have been shown to kill DCs in vitro [52], and it is pos-
sible that a similar mechanism is responsible for DC re-
duction in 4T1 tumor-bearing mice.
Blockade of CD1d in WT mice increased not only locor-
egional DC numbers, but also the priming of tumor-
specific CD8 T cells in dLN and the overall tumor
response to treatment with radiotherapy and anti-
CTLA-4 mAb, suggesting that temporarily “disabling”
iNKT cells was sufficient to enhance Th1 type anti-
tumor immunity. The increased production of IFNγ
in the tumor and spleen of WT mice treated with
RT + anti-CTLA-4 in the presence of CD1d blockade
supports this interpretation.
The overall better anti-tumor immunity and the high
levels of IFNγ seen in treated iNKT−/− mice could be
due to a larger population of immunostimulatory DC
presenting tumor-derived antigens, but may also reflect
skewing of the immune system that develops in BALB/c
mice in the absence of iNKT cells towards Th1 rather
than Th2 immunity [53]. IL-4 producing iNKT cells
(NKT2) were recently described and shown to be the
dominant iNKT subset in the thymus of BALB/c mice,
and were implicated in determining the Th2 dominance of
this mouse strain [53]. Among tumor-infiltrating iNKT
cells, we found a larger percentage (6%) that expressed
markers (CD27 + CD122-) shown to define iNKT2 subset,





















































Figure 6 CD1d blockade enhances systemic IFN-γ response
induced by RT + anti-CTLA-4 blockade. WT or iNKT−/− mice were
treated with local tumor radiotherapy in two fractions of 12 Gy
given on days 13 and 14 post-tumor inoculation. Mice received
anti-CTLA-4 mAb on days 15, 18 and 21. Some mice additionally
received anti-CD1d mAb or isotype mAb i.p. on days 3, 7 and 11
post tumor inoculation. Spleen were harvested at day 22 and
concentration of (A) IFN-γ, (B) IL-10 and (C) IL-4 were measured in
supernatants of PMA + ionomycin stimulated cells. Bars indicate the
mean ± SD of 4 mice/group. **p < 0.005.
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was CD27-CD122-, a phenotype associated with IL-17
production in the thymus [53]. Since IL-17 was undetect-
able in 4T1 tumors, defining the functional differentiation
of iNKT cells in the tumor microenvironment may require
different markers than in the thymus. Importantly, com-
parison between IL-4 levels produced in the tumor and
spleen of tumor-bearing WT and iNKT−/− mice did not
reveal significant differences consistent with differential
Th2 polarization. Intratumoral IL-4 levels were higher in
treated WT than iNKT−/− mice, but unlike IFNγ, IL-4
levels were not modulated by CD1d blockade (Figure 5D).In the spleen IL-4 was increased similarly in treated WT
and iNKT−/− mice (Figure 6C).
iNKT cell role in promoting immune tolerance has been
established in several experimental conditions, including
autoimmune disease models, organ transplant and toler-
ance to oral antigens [23]. While multiple mechanisms
have been suggested to play a role, to our knowledge con-
trol of DCs numbers by iNKT cells has not been previ-
ously documented in immune tolerance models or in the
setting of cancer [23,24,54,55]. However, evidence that hu-
man iNKT cells can kill DCs in vitro [52], suggests that
such mechanism could contribute to immunosuppression
in some tumors and be responsible, at least in part, for the
lack of clinical activity of α-GalCer in cancer patients
[56,57]. Consistent with this hypothesis, administration of
α-GalCer to 4T1 tumor-bearing mice at day 15 post-
tumor inoculation failed to show any effect by itself or in
combination with immunotherapy [25]. By this time, DCs
are low in tumors and dLN (Figure 1), and the remaining
DCs may be insufficient to present α-GalCer and/or may
have acquired a tolerogenic phenotype.
The identity of the CD1d ligand(s) presented by DCs
to iNKT cells in 4T1 tumors and dLN is unknown. The
endogenous lipids presented by CD1d in steady state
conditions are likely to be non-antigenic or elicit toler-
ance. However, metabolic changes in the tumor may lead
to altered lipid biosynthesis and generation of qualitatively
or quantitatively modified CD1d ligands capable of trig-
gering a different functional response of iNKT cells, fur-
ther modulated by the inflammatory environment [23].
Improved understanding of the relationship between lipid
metabolism in cancer and immune regulation will pave
the way to the design of more effective immunotherapies
that can enlist the power of iNKT cells to elicit strong
anti-tumor immunity [58].
Conclusions
In this study we show that local reduction of DCs medi-
ated by iNKT cells regulates the response to immunother-
apy in a mouse model of aggressive breast cancer. The
elimination of APC that cross-present tumor-derived anti-
gens in dLNs was shown previously to be one mechanism
of immunosuppression mediated by Tregs [26]. However,
iNKT cells were believed to consistently perform anti-
tumor activities, while immunosuppressive functions were
ascribed to the non-invariant subset of NKT cells [59].
Here we demonstrate for the first time a novel mechanism
of immune escape mediated by iNKTcells.
These results have important implications for the de-
sign of immunotherapies targeting iNKT cells (reviewed
in [58]). CD1d blockade, or the iNKT-depleting antibody
NKTT120 recently developed for inflammatory diseases
[60], could have a role in treatment of cancers in which
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Figure 7 Response of 4T1 tumor-bearing mice to treatment with local radiotherapy and anti-CD137 mAb is improved in the absence
of iNKT cells. WT or iNKT−/− mice were injected s.c. with 4T1 cells and randomly assigned to treatment groups (N = 5-6 mice/group) on day 13
when tumors became palpable. Local tumor radiotherapy (RT) in two fractions of 12 Gy was given on days 13 and 14 post-tumor inoculation and
anti-CD137 mAb on days 15, 18 and 21. (A) Treatment schema. (B) Tumor growth over time. Fractions indicate the number of mice showing
complete tumor regression. (C) Kaplan-Meier survival curves. (D) Tumor growth in naïve WT mice and iNKT−/− mice that rejected tumors and
were challenged on day 120 with 4T1 cells. Data is representative of 2 independent experiments. *p < 0.05.
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Cells, antibodies and reagents
4T1 is a BALB/c-derived mammary carcinoma that is
highly metastatic and mimics the behavior of triple
negative human breast cancer [39,61]. 4T1 cells were
grown in complete medium consisting of DMEM
(Invitrogen) supplemented with 2 mol/L L-glutamine,
100 U/mL penicillin, 100 μg/mL streptomycin, 2.5 ×
10−5 mol/L 2-mercaptoethanol and 10% fetal bovine
serum (BioWest). Cells were confirmed to be free of
mycoplasma contamination using a mycoplasma de-
tection kit (Sigma). DN32.D3 hybridoma cells, kindly
provided by Masaki Terabe from the NCI Branch of
the National Institutes of Health, were grown in supple-
mented RPMI (Invitrogen) [62]. Anti-CTLA-4 hamster
monoclonal antibody (Clone 9H10) and anti-CD1d rat
monoclonal antibody (Clone 20H2) were purchased
from BioXCell (West Lebanon, NH). Control hamster
IgG (isotype control for anti-CTLA-4) was purchased
from Jackson Immunoresearch Laboratories. Control rat
IgG1 (isotype control for anti-CD1d) was purchased from
BioXCell. A rat IgG2a mAb against mouse CD137 (BMS-
469492, clone 1D8) was provided for these studies by
Bristol-Myers Squibb (Princeton, NJ).Animals
Six to eight-week old WT BALB/c mice were purchased
from Taconic. iNKT−/− (Vα14Jα18-deficient) mice [27] in
the BALB/c background obtained from M. Taniguchi were
bred at Berg Animal Facility at NYU School of Medicine
and used between 6 to 8 weeks of age. All experiments
were approved by the Institutional Animal Care and Use
Committee of NYU Langone Medical Center.
In vivo treatment
Mice were inoculated subcutaneously (s.c.) with 5 × 104
4T1 cells and randomly assigned to treatment groups
13 days later when tumors reached an average diameter
of 5 mm. Radiotherapy was given as previously described
[25] with some modifications. Lightly anesthetized mice
were positioned on a dedicated plexiglass tray with only
the tumor area exposed to radiation while the rest of the
body was protected by lead shielding. Radiotherapy was
given using the Small Animal Radiation Research Plat-
form (SARRP) (Gulmay Medical, Suwanee, GA) [63] in
two doses of 12 Gy each on days 13 and 14 post tumor
inoculation. Control hamster IgG and anti-CTLA-4 or
anti-CD137/4-1BB mAbs were given at 200 μg i.p. at 1,
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Figure 8 CD1d blockade enhances production of IFN-γ
by tumor-specific cells generated by RT + anti-CD137
co-stimulation. WT or iNKT−/− mice were treated with local
tumor radiotherapy in two fractions of 12 Gy given on days 13
and 14 post-tumor inoculation. Mice received anti-CD137 mAb on days
15, 18 and 21. Some mice additionally received anti-CD1d mAb or
isotype control on days 3, 7 and 11 post tumor inoculation. Cells from
tumor-draining lymph nodes were collected on day 23 and stimulated
with feeder cells pre-loaded with irrelevant peptide pMCMV (open
circles) or AH-1-A5 (filled circles). Secreted IFN-γ in the supernatant was
measured 48 hours later. Each symbol represents an individual mouse.
Bars indicate the mean ± SD of 3–5 mice/group. *p < 0.05, ***p < 0.0005.
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mAb (Clone 20H2) at 100 μg i.p. on days 3, 7 and 11
post tumor inoculation. Tumors were measured every
2–3 days until death or sacrifice when tumor dimensions
exceeded 5% of body weight or if animals showed signs
of significant pain or distress due to metastatic disease.
In some experiments, mice that eradicated the tumor
after treatment and remained tumor-free for at least
120 days were inoculated in the contralateral flank with
4T1 cells and tumor growth monitored. A group of
naïve mice was similarly challenged with 4T1 cells as
control.
Immunohistochemistry
4T1 tumors and dLNs were harvested on indicated days,
fixed in freshly prepared 4% paraformaldehyde for 1 hr at
4°C and incubated overnight in 30% sucrose. Tumors were
then frozen in optimum cutting temperature (OCT)
medium and stored at −80°C. Sections (5 μm) were treated
with 3% H2O2 in PBS for 30 minutes in order to eliminate
endogenous peroxide activity. After blocking in 4% ham-
ster serum for an hour and three washes with PBS, anti-
mouse CD11c eFluor 615 (eBioscience, San Diego, CA)
was applied at a 1/100 dilution in 1% BSA for 1 hour,
followed by three washes and incubation in HRP-conjugated streptavidin (Jackson ImmunoResearch, West
Grove, PA) at a 1/2,000 dilution in 1% BSA for 30 minutes.
To amplify the signal, slides were subject to two rounds of
biotin-tyramide amplification (PerkinElmer, Melville, NY)
using manufacturer’s suggested protocol. The slides were
counterstained with DAPI, mounted with Vectashield and
images obtained using a Nikon Eclipse 800 deconvolution
microscope. Positive cells were counted from at least 3
randomly selected fields (20× magnification).Flow cytometry
Lymph nodes and minced tumors were digested using a
cocktail of 1.67 Wünsch U/mL Liberase TL (Roche) and
0.2 mg/mL DNAse (Roche) as previously described
[40,64]. After lysis of red blood cells single cell suspen-
sions were filtered through a 40-μm nylon cell strainer.
Live cells were distinguished using Fixable Viability Dye
eFluor 660 (eBioscience) prior to flow staining. All sam-
ples were incubated with anti-mouse CD16/32 (Fc block)
for 10 minutes followed by staining for various surface
markers for 30 minutes at 4°C. The following antibodies
were used (all purchased from eBiosciences): PE-Cy7-
conjugated anti-mouse CD11c, Alexa Fluor 700-conjugated
anti-mouse CD86, PE-conjugated anti-mouse CD80, PE-
conjugated anti-mouse CD1d, PE-conjugated anti-mouse
CD70, FITC-conjugated anti-mouse CD40 and Alexa
Fluor 700-conjugated anti-mouse MHC Class I (H-2Kd/
Dd), FITC-conjugated anti-mouse CD27, PECy7-conjugated
anti-mouse CD3ε, APC-conjugated anti-mouse CD122,
Alexa Fluor 700-conjugated anti-mouse CD4. iNKT cells
were identified by staining with mouse CD1d/PBS-57 or
CD1d/unloaded tetramers (NIH Tetramer Core Facility)
for 30 minutes at room temperature [65]. All samples
were analyzed using a BD LSR II flow cytometer and
FlowJo version 8.7.5 (Tree Star).Ex vivo cytokine production
Single cell suspensions (3 × 105 per well) from draining
lymph nodes of 4T1 tumor-bearing WT or iNKT−/− mice
were cultured in complete T-cell medium in 48-well tissue
culture plates with irradiated (12 Gy) feeder cells (3 × 106)
prepared from the spleen of healthy BALB/c mice
pre-loaded with tumor-derived peptides (AH-1-A5) or
an H-2Ld-binding irrelevant peptide (pMCMV) used at a
final concentration of 1 μg/mL. Peptide sequences are
SPSYAYHQF (AH-1-A5) [66], and YPHFMPTNL (pMCMV)
[66]. After 48 hours, supernatants were collected and
stored at −80°C. Secreted IFN-γ was measured from
duplicate wells using Flowcytomix kit (eBioscience,
San Diego, CA). Background IFN-γ production from
supernatants of cells cultured in complete T-cell media
alone was subtracted. Spleen cell suspensions (106) from
4T1 tumor-bearing mice were cultured in a 24-well tissue
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Stimulation Cocktail Mix (eBioscience) for 48 hours.Intratumoral cytokines
Freshly harvested tumors were immediately frozen in li-
quid nitrogen and stored at −80°C. To isolate total protein,
tissues were thawed on ice, minced and homogenized in
lysis buffer (10 mM Tris–HCl pH8.0, 150 mM NaCl, 1%
NP-40, 10% glycerol, 5 mM EDTA) and protease inhibitor
cocktail (Roche). Total volume (μL) of lysis buffer used
was equal to 5× weight of tumor tissue (mg). Lysates were
sonicated in 4°C using a 7-minute regimen of 30s intermit-
tent on and off. Samples were spun at 14,000 rpm for
15 minutes at 4°C, supernatants collected and protein con-
centrations determined using Bradford assay. Samples
were stored at −80°C. Cytokines were measured from du-
plicates wells using multi-analyte Flowcytomix kit.Statistical analysis
Random coefficients regression (RCR) was used to assess
the effect of treatment on tumor growth. The dependent
variable was the natural log of tumor volume at all avail-
able times; log volumes were used since the change in
log volume over the course of follow-up was well ap-
proximated as linear within each treatment arm. Log rank
tests were used to compare treatment arms in terms of sur-
vival. The Kaplan-Meier method was used to estimate me-
dian survival times and the log cumulative hazard
transformation was used to derive 95% confidence limits for
median survival in each arm. All reported p values are two-
sided and statistical significance defined as p < 0.05. SAS 9.3
(SAS Institute, Cary, NC) was used for all computations.Additional files
Additional file 1: Figure S1 Anti-CD1d mAb blocks cytokine
production by DN32.D3 NKT-like hybridoma cells stimulated with
α-GalCer-loaded DCs. CD11c+ bone-marrow derived dendritic cells
(BMDC) from healthy BALB/c mice were plated in 24-well tissue culture
plate (2×104/well) and incubated with 100 ng/mL α-GalCer overnight,
washed extensively and incubated overnight with fresh media containing
anti-CD1d at indicated final concentrations. Cells were washed again
before the addition of DN32.D3 hybridoma cells (105/well). Supernatants
were collected three days later and cytokines measured.
Additional file 2: Figure S2 Anti-CD1d mAb does not deplete
CD1d-expressing cells in vivo. Healthy WT mice (N = 4/group) were
given isotype or anti-CD1d mAb i.p. (200 μg/mouse) every 4 days for a
total of 3 doses. Two days after the last dose, mice were euthanized and
single cell suspensions from digested spleens collected for flow staining
of (A) DC, (B) myeloid cells, (C) B-cells and (D) macrophage populations.
Additional file 3: Figure S3 Anti-CD1d mAb does not induce
stimulation of CD1d-expressing APCs. Splenocytes from naïve WT
or iNKT−/− mice (n = 4/group) were stimulated in vitro with 10 μg/mL
α-CD1d or isotype control mAbs for 48 hours. As a positive control,
splenocytes were stimulated with LPS (1 μg/mL). Supernatants were
collected and measured for secreted (A) IL-10, (B) IFN-γ, (C) IL-12p70
and (D) IL-4.Additional file 4: Figure S4 Local tumor radiotherapy and CD137
co-stimulation used alone are ineffective in prolonging survival of
4T1 tumor-bearing mice. WT and iNKT−/− mice were injected s.c. with
4T1 cells and randomly assigned to treatment groups (n = 5-6/group) on
day 13 when tumors became palpable. Local tumor radiotherapy (RT)
was given in two fractions of 12 Gy on days 13 and 14 post-tumor
inoculation. Mice received anti-CD137 mAb on days 15, 18 and 21.
Kaplan-Meier curves were generated from survival data of each mouse
calculated as time (days) from date of inoculation until death or euthanasia.
Median survival (days) in each treatment group is indicated in parenthesis.
Data is representative of 2 independent experiments.
Additional file 5: Figure S5 iNKT subset compartments in 4T1
tumors and tumor-draining lymph nodes. WT mice were injected
s.c. with 4T1 cells. On day 15, tumor samples from three mice were pooled
and digested to obtain single cell suspensions. (A) Intratumoral iNKT cells
were identified using mouse CD1d/PBS-57 tetramers. Expression of surface
CD122 and CD27 antigens were assessed on CD3+ CD1d/PBS-57 tetramer +
populations to identify iNKT1 (CD27 + CD122+) and iNKT2 (CD27-CD122+)
subsets. (B) The relative abundance of iNKT cells in the tumor and draining
lymph nodes is shown as a percentage of total CD3 cells. (C) The relative
abundance of iNKT1 (white bars) and iNKT2 (black bars) subsets is shown as
a percentage of total CD3+ CD1d/PBS-57 tetramer + cells. Bars indicate the
mean ± SD of three samples. **p < 0.005.Abbreviations
α-GalCer: Alpha galactosylceramide; APC: Antigen presenting cells; BMDC: Bone
marrow-derived dendritic cells; CD: Cluster of differentiation; CTL: Cytotoxic
T lymphocytes; DCs: Dendritic cells; dLN: Draining lymph node; Gy: Gray;
IFN-γ: Interferon gamma; IHC: Immunohistochemistry; iNKT−/−: Invariant natural
killer T cell-deficient; i.p.: Intraperitoneal; mAb: Monoclonal antibody;
MHC: Major histocompatibility complex; ndLN: Non-draining lymph node;
NK: Natural killer; PBS: Phosphate buffered saline; PMA: Phorbol 12-myristate
13-acetate; RT: Radiotherapy; s.c.: Subcutaneous; TAA: Tumor-associated
antigens; Th1: T-helper type 1; Th2: T-helper type 2; Tregs: Regulatory T cells;
WT: Wild type.
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